卡度尼利单抗致免疫性心肌炎1例
One case of immune-mediated myocarditis induced by Cadonilimab monoclonal antibody
丁娣 1孙旭森 1钱晓琳 1王韦 1张政1
作者信息
- 1. 复旦大学附属中山医院青浦分院心血管内科(上海,201700)
- 折叠
摘要
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已用于治疗多种恶性肿瘤,使肿瘤患者受益.卡度尼利单抗是2022年6月获批的首个PD-1/CTLA-4肿瘤双ICIs,迄今为止尚无使用卡度尼利单抗所致的ICIs相关性心肌炎的报道.本文介绍了 1例使用卡度尼利单抗3个周期后诊断为重症ICIs相关性心肌炎,行糖皮质激素治疗后病情显著改善的病例.此病例强调了卡度尼利单抗诱导ICIs相关性心肌炎的潜在风险,为此类新型免疫抑制剂导致心肌炎的诊断和治疗提供思路.
Abstract
Immune checkpoint inhibitors(ICIs)have been used to treat various malignant tumors,and benefit cancer patients.Cadonilimab is the first PD-1/CTLA-4 tumor dual ICIs approved in June 2022,and there have been no reports of ICIs associated myocarditis caused by Cadonilimab.This article introduces one case of severe ICIs related myocarditis diagnosed after 3 cycles of using Cadonilimab,and his condition was improved significant-ly after glucocorticoids treatment.This case highlights the potential risk of ICIs related myocarditis induced by Cadonilimab,providing insights for the diagnosis and treatment of ICIs related myocarditis.
关键词
卡度尼利单抗/免疫检查点抑制剂/免疫性心肌炎Key words
Cadonilimab/immune checkpoint inhibitors/immune myocarditis引用本文复制引用
出版年
2024
NETL
NSTL
万方数据